scholarly journals Number Needed to Treat Among Therapies for Patients with Moderate to Severe Plaque Psoriasis: Clinical Perspective of Results from a Network Meta-Analysis

2021 ◽  
Vol 5 (6) ◽  
pp. s54
Author(s):  
C Leonardi ◽  
K Fahrbach ◽  
B Neupane ◽  
A Armstrong ◽  
K Gordon ◽  
...  
Keyword(s):  
Plaque Psoriasis ◽  
Meta Analysis ◽  
Number Needed To Treat ◽  
Clinical Perspective ◽  
Severe Plaque Psoriasis

N/A

scholarly journals Number needed to treat for interleukin inhibitors approved for the treatment of moderate-to-severe plaque psoriasis in Italy

2021 ◽  
Vol 8 ◽  
pp. 53-57
Author(s):  
Roberto Ravasio ◽  
Antonio Costanzo ◽  
Silvia Antonelli ◽  
Alessia Maiorino ◽  
Serena Losi
Keyword(s):  
Plaque Psoriasis ◽  
Meta Analysis ◽  
Severity Index ◽  
Number Needed To Treat ◽  
Severe Plaque Psoriasis ◽  
Cochrane Database ◽  
Biological Treatments ◽  
Effective Option ◽  
Interleukin Inhibitors ◽  
Systemic Therapies

Background: Interleukin (IL) inhibitors achieve greater levels of efficacy than older systemic therapies. We calculated the number needed to treat (NNT) of ixekizumab compared with other IL inhibitors approved in Italy for the treatment of moderate-to-severe plaque psoriasis. Methods: The clinical efficacy was evaluated in terms of NNT, based on the results of a recent network meta-analysis (NMA) by the Cochrane Database of Systematic Reviews. The NMA investigated many systemic and biological treatments, but this analysis compared only the efficacy of the following IL inhibitors – brodalumab, guselkumab, ixekizumab, risankizumab, secukinumab, tildrakizumab and ustekinumab – for patients with moderate-to-severe plaque psoriasis. Drugs were compared and ranked according to effectiveness considering the PASI (Psoriasis Area and Severity Index) 90 score. Results: One-hundred and forty trials (51,749 patients) were included in the NMA. Considering the proportion of patients who achieve PASI90, ixekizumab showed the lowest NNT among all comparators (ixekizumab 2.01 [2.46-3.00]; risankizumab 2.05 [2.50-3-05]; guselkumab 2.16 [2.68-3.36]; secukinumab 2.40 [2.90-3.51]; brodalumab 2.61 [3.18-3.88]; ustekinumab 3.44 [4.12-4.95]; tildrakizumab 3.10 [4.15-5.59]. Conclusion: The findings show that ixekizumab is the most effective option (NNT) for the treatment of moderate-to-severe plaque psoriasis.

PBI3 Comparative Efficacy of Bimekizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Network Meta-Analysis

2021 ◽  
Vol 24 ◽  
pp. S14
Author(s):  
A. Armstrong ◽  
K. Reich ◽  
R.B. Warren ◽  
V. Taieb ◽  
K. Fahrbach ◽  
...  
Keyword(s):  
Plaque Psoriasis ◽  
Meta Analysis ◽  
Comparative Efficacy ◽  
Severe Plaque Psoriasis

Placebo Response in Phase 3 Trials of Systemic Therapies for Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Meta-Analysis

Dermatology ◽  
2020 ◽  
pp. 1-8
Author(s):  
Danni Ambikaibalan ◽  
Anna Sophie Quaade ◽  
Anne-Sofie Halling ◽  
Jacob P. Thyssen ◽  
Alexander Egeberg
Keyword(s):  
Systematic Review ◽  
Plaque Psoriasis ◽  
Meta Analysis ◽  
Placebo Response ◽  
Phase 3 ◽  
Severe Plaque Psoriasis ◽  
Systemic Therapies

Efficacy of Brodalumab for Moderate to Severe Plaque Psoriasis: A Canadian Network Meta-Analysis

2020 ◽  
Vol 24 (6) ◽  
pp. 561-572
Author(s):  
Weiguang Xue ◽  
Paranjoy Saharia ◽  
Emma Gray ◽  
Shoghag Khoudigian-Sinani ◽  
Véronique Gaudet ◽  
...  
Keyword(s):  
Relative Risk ◽  
Plaque Psoriasis ◽  
Meta Analysis ◽  
Credible Interval ◽  
Severity Index ◽  
Biologic Agents ◽  
Sensitivity Analyses ◽  
Induction Phase ◽  
Significant Heterogeneity ◽  
Severe Plaque Psoriasis

Background Several treatments for plaque psoriasis are available, but it remains challenging for physicians to make informed treatment decisions due to a lack of head-to-head trials. Objectives This network meta-analysis (NMA) compares the efficacy of brodalumab to other biologic agents in Canada for moderate-to-severe plaque psoriasis. Methods A systematic literature review of randomized controlled trials (RCTs) published before October 2017 was conducted to populate the NMA. Comparators included etanercept, infliximab, adalimumab, ustekinumab, secukinumab, ixekizumab, guselkumab, and placebo. The primary outcome was the psoriasis area and severity index (PASI) response at the end of induction phase. A random effects Bayesian multinomial likelihood and probit link model analyzed PASI 75, 90, and 100 responses. Inconsistency and heterogeneity were assessed. Sensitivity analyses were conducted to explore potential effect modifiers like baseline PASI score, age, and weight. Results A total of 43 RCTs were included. Brodalumab 210 mg had significantly better PASI response than etanercept, ustekinumab, adalimumab, secukinumab, and guselkumab and comparable responses to infliximab and ixekizumab. Relative risk of PASI 90 response for brodalumab varied from 2.84 (95% credible interval [CrI]: 2.35-3.52, P < .05) to 0.99 (95% CrI: 0.88-1.11, ns) compared to etanercept and ixekizumab. This was similar across PASI 75 responses, but a larger relative risk between brodalumab and all comparators except ixekizumab was observed for PASI 100. No significant heterogeneity or inconsistencies were identified. The results were consistent across sensitivity analyses, indicating robustness of the results. Conclusion Brodalumab 210 mg has efficacy superior to most biologic agents for moderate-to-severe plaque psoriasis in Canada.

scholarly journals Efficacy and safety of guselkumab for the treatment of patients with moderate-to-severe plaque psoriasis: A metaanalysis of randomized clinical trials

2020 ◽  
Vol 19 (2) ◽  
pp. 433-440
Author(s):  
Xing-Bao Tao ◽  
Yin-Qiu Huang ◽  
Yi-Hong Zhou ◽  
Lv-Lang Zhang ◽  
Yao-Kai Chen
Keyword(s):  
Quality Of Life ◽  
Clinical Trials ◽  
Adverse Events ◽  
Plaque Psoriasis ◽  
Meta Analysis ◽  
Controlled Trials ◽  
Double Blind ◽  
Severe Plaque Psoriasis ◽  
Central Registry

Purpose: To conduct a systematic analysis on data from randomized controlled trials (RCTs) on different doses of guselkumab, and provide high-quality evidence for its use in the treatment of patients with moderate-to-severe plaque psoriasis (PsO). Methods: Related studies were searched using online search engines including MEDLINE, PubMed, and central registry of Cochrane controlled trials from January 2001 to October 2017. Only randomized, placebo-controlled, double-blind clinical trials involving guselkumab- and placebo-treated PsO subjects were included. Results: Five eligible double-blind, randomized, and placebo-controlled trials involving patients with moderate-to-severe PsO subjects treated with guselkumab were included. Compared with the placebo groups, the proportion of patients with improvements in Psoriasis Area and Severity Index (PASI) 75 (RR= 12.14; 95% CI= 9.11-16.16; p < 0.001); PASI 90 (RR= 23.26; 95% CI =14.57-37.13; p < 0.001), and PASI 100 (RR = 37.66; 95% CI = 15.81-89.69; p < 0.001) were significantly higher than those in guselkumab-treated groups. Furthermore, the guselkumab-treated groups showed significant decreases in Physician’s Global Assessment (PGA) score (RR = 10.46; 95% CI = 7.96-13.83; p < 0.001) and the Dermatology Life Quality Index (DLQI) score (SMD = -1.3; 95% CL = -1.4 to -1.19; p < 0.001), when compared with the placebo groups. However, there were no significant differences in adverse events (AEs) (RR = 1.01; 95% CL = 0.93-1.11; p > 0.05); severe adverse events (SAEs) (RR = 1.32; 95% CI =0.69-2.54; p > 0.05) and study discontinuations (RR = 0.79; 95% CI = 0.42-1.48; p > 0.05) between the two groups. Conclusion: This meta-analysis summarizes available evidence for the use of guselkumab in psoriasis. The results suggest that guselkumab is superior to placebo in moderate-to-severe psoriasis, and is welltolerated, effective, and safe in improving the severity of disease and quality of life. Keywords: Guselkumab, Effectiveness, Safety, Plaque psoriasis, Meta-analysis, Quality of life

Sign in / Sign up

Export Citation Format

Share Document